Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
CRSP
CRSP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRSP News
CRISPR Therapeutics Plans $350 Million Private Debt Offering
1h ago
stocktwits
CRISPR Therapeutics Plans $350 Million Convertible Notes Offering
1h ago
NASDAQ.COM
TD Cowen Upgrades Rivian to Buy, Raises Price Target
2h ago
stocktwits
S&P 500 Futures Hold Steady in Pre-Market Session; Vertex Pharmaceuticals and UFP Industries Take the Lead
3h ago
Barron's
CRISPR Therapeutics to Offer $350M Convertible Senior Notes
3h ago
seekingalpha
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
20h ago
Benzinga
Analysis of Gene Editing Drug Market Prospects
5d ago
Fool
Investment Outlook in Gene Editing Market
5d ago
NASDAQ.COM
CRISPR Therapeutics: Potential and Challenges in Gene Editing
Mar 02 2026
Fool
CRISPR Therapeutics Faces Significant Challenges Amid Slow Rollout
Mar 02 2026
NASDAQ.COM
Cathie Wood's Latest Investment Moves in Ark Innovation ETF
Mar 01 2026
Fool
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth
Feb 26 2026
Benzinga
Crispr Therapeutics Rises 5% Amid Acquisition Speculation
Feb 26 2026
seekingalpha
FDA Unveils New Guidance to Accelerate Rare Disease Therapy Approvals
Feb 23 2026
seekingalpha
CRISPR Therapeutics: Promising Pipeline and Risks Ahead
Feb 20 2026
Fool
Promising Future for CRISPR Therapeutics
Feb 20 2026
NASDAQ.COM
Show More News
